FDA Enhances Speed and Transparency of Actions Taken Against Misconduct in Drug and Device Development

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: FDA Enhances Speed and Transparency of Actions Taken Against Misconduct in Drug and Device Development

FDA Enhances Speed and Transparency of Actions Taken Against Misconduct in Drug and Device Development
Fri, 07 Aug 2009 00:00:00 -0500

The Food and Drug Administration today announced it has stepped up its efforts to prevent non-compliant investigators and others from participating in new product development. FDA’s procedures for debarment and disqualification have been enhanced to better protect participants in clinical studies and for ensuring the safety and effectiveness of the medical products marketed to the American public.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@xxxxxxxxxxxxxxx
• Other inquiries? webmail@xxxxxxxxxx

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420